Jan H.M. Schellens

59.2k total citations · 14 hit papers
882 papers, 41.1k citations indexed

About

Jan H.M. Schellens is a scholar working on Oncology, Molecular Biology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Jan H.M. Schellens has authored 882 papers receiving a total of 41.1k indexed citations (citations by other indexed papers that have themselves been cited), including 564 papers in Oncology, 346 papers in Molecular Biology and 159 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Jan H.M. Schellens's work include Cancer Treatment and Pharmacology (184 papers), Colorectal Cancer Treatments and Studies (163 papers) and Cancer therapeutics and mechanisms (139 papers). Jan H.M. Schellens is often cited by papers focused on Cancer Treatment and Pharmacology (184 papers), Colorectal Cancer Treatments and Studies (163 papers) and Cancer therapeutics and mechanisms (139 papers). Jan H.M. Schellens collaborates with scholars based in Netherlands, United States and United Kingdom. Jan H.M. Schellens's co-authors include Jos H. Beijnen, Alwin D. R. Huitema, Hilde Rosing, Dick Pluim, Alfred H. Schinkel, Irma Meijerman, Olaf van Tellingen, David S. Boss, Rolf W. Sparidans and Marja Mergui‐Roelvink and has published in prestigious journals such as New England Journal of Medicine, Cell and Journal of Biological Chemistry.

In The Last Decade

Jan H.M. Schellens

876 papers receiving 40.3k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Inhibition of Poly(ADP-Ribose) Polymerase in Tumors from BRCA Mutation Carriers

2009 2.7k citations Peter C.C. Fong, David S. Boss et al. profile →
Subcellular localization and distribution of the breast cancer resistance protein transporter in normal human tissues.

2001 920 citations Jan H.M. Schellens et al. PubMed profile →
A Phase I and Pharmacological Study with Imidazolium- trans- DMSO-imidazole-tetrachlororuthenate, a Novel Ruthenium Anticancer Agent

2004 760 citations Dick Pluim, Jos H. Beijnen et al. Clinical Cancer Research profile →
Poly(ADP)-Ribose Polymerase Inhibition: Frequent Durable Responses in BRCA Carrier Ovarian Cancer Correlating With Platinum-Free Interval

2010 745 citations Peter C.C. Fong, Timothy A. Yap et al. Journal of Clinical Oncology profile →
Photodynamic Therapy in Oncology

2006 619 citations Jan H.M. Schellens et al. profile →
Dabrafenib and Trametinib Treatment in Patients With Locally Advanced or Metastatic BRAF V600–Mutant Anaplastic Thyroid Cancer

2017 607 citations Jan H.M. Schellens, Jean Charles Soria et al. Journal of Clinical Oncology profile →
Potent and specific inhibition of the breast cancer resistance protein multidrug transporter in vitro and in mouse intestine by a novel analogue of fumitremorgin C.

2002 590 citations Jan H.M. Schellens et al. PubMed profile →
Clinical Pharmacokinetics of Therapeutic Monoclonal Antibodies

2010 558 citations Alwin D. R. Huitema, Jan H.M. Schellens et al. profile →
Approaching tumour therapy beyond platinum drugs

2011 450 citations Jan H.M. Schellens, Jos H. Beijnen et al. profile →
Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Dihydropyrimidine Dehydrogenase Genotype and Fluoropyrimidine Dosing: 2017 Update

2017 406 citations Jan H.M. Schellens et al. profile →
Enhancing antitumor response by combining immune checkpoint inhibitors with chemotherapy in solid tumors

2019 404 citations Neeltje Steeghs, Jos H. Beijnen et al. profile →
Dabrafenib plus trametinib in patients with BRAFV600E-mutated biliary tract cancer (ROAR): a phase 2, open-label, single-arm, multicentre basket trial

2020 314 citations Ulrik Lassen, Jan H.M. Schellens et al. profile →
Phosphatidylinositol 3-Kinase α–Selective Inhibition With Alpelisib (BYL719) in PIK3CA-Altered Solid Tumors: Results From the First-in-Human Study

2018 302 citations Dejan Juric, Jordi Rodón et al. Journal of Clinical Oncology profile →
Dabrafenib plus trametinib in patients with BRAF V600E-mutant anaplastic thyroid cancer: updated analysis from the phase II ROAR basket study

2022 183 citations Jan H.M. Schellens, Jean‐Charles Soria et al. profile →

Peers

Countries citing papers authored by Jan H.M. Schellens

Since Specialization

Citations

This map shows the geographic impact of Jan H.M. Schellens's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jan H.M. Schellens with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jan H.M. Schellens more than expected).

Fields of papers citing papers by Jan H.M. Schellens

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jan H.M. Schellens. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jan H.M. Schellens. The network helps show where Jan H.M. Schellens may publish in the future.

Co-authorship network of co-authors of Jan H.M. Schellens

This figure shows the co-authorship network connecting the top 25 collaborators of Jan H.M. Schellens. A scholar is included among the top collaborators of Jan H.M. Schellens based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jan H.M. Schellens. Jan H.M. Schellens is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Phase I and Pharmacologic Study of Olaparib in Combination with High-dose Radiotherapy with and without Concurrent Cisplatin for Non–Small Cell Lung Cancer 2020 ·Clinical Cancer Research ·(unknown), Michel M. van den Heuvel, Judi van Diessen, Heike Peulen, Erik van Werkhoven, Adrianus J. de Langen, Ferry Lalezari, Dick Pluim, Manon Verwijs-Janssen, Conchita Vens, Jan H.M. Schellens, Neeltje Steeghs, Marcel Verheij, Baukelien van Triest	39
2	Age-Associated Hematological Toxicity in Patients with Metastatic Castration-Resistant Prostate Cancer Treated with Docetaxel in Clinical Practice 2019 ·Drugs & Aging ·(unknown), (unknown), (unknown), Hans-Martin Otten, Andries M. Bergman, Jan H.M. Schellens, Jos H. Beijnen, Alwin D. R. Huitema	5
3	Phase I Study of CC-486 Alone and in Combination with Carboplatin or nab-Paclitaxel in Patients with Relapsed or Refractory Solid Tumors 2018 ·Clinical Cancer Research ·Daniel D. Von Hoff, Drew Rasco, Elisabeth I. Heath, Pamela N. Münster, Jan H.M. Schellens, Nicolás Isambert, Christophe Le Tourneau, Bert H. O’Neil, Ron H.J. Mathijssen, José A. López-Martín, W. Jeff Edenfield, Miguel Martín, Patricia LoRusso, Gordon L. Bray, Jorge DiMartino, Aaron Nguyen, Kejian Liu, Eric Laille, Johanna C. Bendell	27
4	Phosphatidylinositol 3-Kinase α–Selective Inhibition With Alpelisib (BYL719) in PIK3CA-Altered Solid Tumors: Results From the First-in-Human Study breakdown → 2018 ·Journal of Clinical Oncology ·Dejan Juric, Jordi Rodón, Josep Tabernero, Filip Jankú, Howard A. Burris, Jan H.M. Schellens, Mark R. Middleton, Jordan Berlin, Martin Schüler, Marta Gil-Martín, Hope S. Rugo, Ruth Seggewiss‐Bernhardt, Alan Huang, Douglas Bootle, David Demanse, Lars Blumenstein, Christina Coughlin, Cornelia Quadt, José Baselga	302
5	Development and validation of a liquid chromatography-tandem mass spectrometry assay for the quantification of lurbinectedin in human plasma and urine 2018 ·Journal of Pharmaceutical and Biomedical Analysis ·(unknown), Hilde Rosing, Rubin Lubomirov, Pablo Avilés, Salvador Fudio, Matthijs M. Tibben, (unknown), Jan H.M. Schellens, Jos H. Beijnen	5
6	Therapeutic drug monitoring of small molecule kinase inhibitors in oncology in a real‐world cohort study: does age matter? 2018 ·British Journal of Clinical Pharmacology ·(unknown), (unknown), Julie M. Janssen, Hilde Rosing, Jan H.M. Schellens, Jos H. Beijnen, Neeltje Steeghs, Alwin D. R. Huitema	13
7	Development, validation, and clinical application of a high-performance liquid chromatography-tandem mass spectrometry assay for the quantification of total intracellular β-decitabine nucleotides and genomic DNA incorporated β-decitabine and 5-methyl-2′-deoxycytidine 2018 ·Journal of Pharmaceutical and Biomedical Analysis ·(unknown), Hilde Rosing, (unknown), Aram Oganesian, Jan H.M. Schellens, Jos H. Beijnen	7
8	Treatment of Peritoneal Dissemination in Stomach Cancer Patients With Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC): Rationale and Design of the PERISCOPE Study 2017 ·JMIR Research Protocols ·Rosa T. van der Kaaij, H.J. Braam, Henk Boot, Maartje Los, Annemieke Cats, Cecile Grootscholten, Jan H.M. Schellens, Arend G. J. Aalbers, Alwin D. R. Huitema, Catherijne A. J. Knibbe, Djamila Boerma, Marinus J. Wiezer, Bert van Ramshorst, Johanna W. van Sandick	13
9	Liquid chromatography–tandem mass spectrometric assay for the T790M mutant EGFR inhibitor osimertinib (AZD9291) in human plasma 2016 ·Journal of Chromatography B ·Johannes J.M. Rood, Mark T. J. van Bussel, Jan H.M. Schellens, Jos H. Beijnen, Rolf W. Sparidans	39
10	First-in-Human Phase I Study of GSK2126458, an Oral Pan-Class I Phosphatidylinositol-3-Kinase Inhibitor, in Patients with Advanced Solid Tumor Malignancies 2015 ·Clinical Cancer Research ·Pamela N. Münster, Rahul Aggarwal, David S. Hong, Jan H.M. Schellens, Ruud van der Noll, Jennifer M. Specht, Petronella O. Witteveen, Theresa L. Werner, Elizabeth Claire Dees, Emily K. Bergsland, Neeraj Agarwal, Joseph F. Kleha, M. Durante, Laurel M. Adams, Deborah A. Smith, Thomas A. Lampkin, Shannon R. Morris, Razelle Kurzrock	83
11	[Threshold value for reimbursement of costs of new drugs: cost-effectiveness research and modelling are essential links]. 2015 ·PubMed ·Geert Frederix, Anke M. Hövels, Johan L. Severens, Jan A. M. Raaijmakers, Jan H.M. Schellens	0
12	A Phase I Monotherapy Study of RG7212, a First-in-Class Monoclonal Antibody Targeting TWEAK Signaling in Patients with Advanced Cancers 2014 ·Clinical Cancer Research ·Ulrik Lassen, Didier Meulendijks, L.L. Siu, Vaios Karanikas, Morten Mau‐Sørensen, Jan H.M. Schellens, Derek J. Jonker, Aaron R. Hansen, Mary Ellen Simcox, Kathleen Schostack, Dean Bottino, Hua Zhong, Markus Roeßler, (unknown), (unknown), David Geho, Ka Wang, Mark DeMario, Glenwood D. Goss	32
13	Dose–Response Relationship in Phase I Clinical Trials: A European Drug Development Network (EDDN) Collaboration Study 2014 ·Clinical Cancer Research ·Víctor Moreno, David Olmos, Carlos Gomez‐Roca, Philippe A. Cassier, Rafael Morales‐Barrera, (unknown), Elisa Gallerani, André T. Brunetto, Patrick Schöffski, Silvia Marsoni, Jan H.M. Schellens, Nicolas Penel, Emile E. Voest, Jeffrey Evans, Ruth Plummer, Richard H. Wilson, Jean Charles Soria, Josep Tabernero, Jaap Verweij, Stan B. Kaye	14
14	Phase I Expansion and Pharmacodynamic Study of the Oral MEK Inhibitor RO4987655 (CH4987655) in Selected Patients with Advanced Cancer with RAS–RAF Mutations 2014 ·Clinical Cancer Research ·Lisa Zimmer, Fabrice Barlési, Maria Martinez‐García, Véronique Dièras, Jan H.M. Schellens, Jean‐Philippe Spano, Mark R. Middleton, Emiliano Calvo, L. Paz-Ares, James Larkin, Simon Pacey, Miro Venturi, Françoise Kraeber‐Bodéré, Jean Tessier, Wilfried Eberhardt, Michel Pâques, Ernesto Guarin, Valérie Méresse, Jean‐Charles Soria	59
15	Phase I Dose-Escalation Study of the Safety, Pharmacokinetics, and Pharmacodynamics of the MEK Inhibitor RO4987655 (CH4987655) in Patients with Advanced Solid Tumors 2012 ·Clinical Cancer Research ·Suzanne Leijen, Mark R. Middleton, Patricia Tresca, Françoise Kraeber‐Bodéré, Véronique Dièras, M. E. Scheulen, Avinash Gupta, Vanesa López-Valverde, Zhixin Xu, Ruediger Rueger, Jean Tessier, Eliezer Shochat, (unknown), (unknown), Jan H.M. Schellens, Wilfried Eberhardt	55
16	Relationship between Single Nucleotide Polymorphisms and Haplotypes in DPYD and Toxicity and Efficacy of Capecitabine in Advanced Colorectal Cancer 2011 ·Clinical Cancer Research ·Maarten J. Deenen, Jolien Tol, Artur M Burylo, Valerie D. Doodeman, Anthonius de Boer, Andrew Vincent, Henk‐Jan Guchelaar, Paul H.M. Smits, Jos H. Beijnen, Cornelis J.A. Punt, Jan H.M. Schellens, Annemieke Cats	150
17	Phase I Dose-Escalation Study of the Pan-HER Inhibitor, PF299804, in Patients with Advanced Malignant Solid Tumors 2011 ·Clinical Cancer Research ·Pasi A. Jänne, David S. Boss, D. Ross Camidge, Carolyn D. Britten, Jeffrey A. Engelman, Edward B. Garon, Feng Guo, Steven Wong, Jane Liang, Stephen P. Letrent, Robert Millham, Ian Taylor, S. Gail Eckhardt, Jan H.M. Schellens	149
18	Poly(ADP)-Ribose Polymerase Inhibition: Frequent Durable Responses in BRCA Carrier Ovarian Cancer Correlating With Platinum-Free Interval breakdown → 2010 ·Journal of Clinical Oncology ·Peter C.C. Fong, Timothy A. Yap, David S. Boss, Craig P. Carden, Marja Mergui‐Roelvink, Charlie Gourley, Jacques De Grève, Jan Lubiński, Susan Shanley, Christina Messiou, Roger A’Hern, Andrew Tutt, Alan Ashworth, John Stone, James Carmichael, Jan H.M. Schellens, Johann S. de Bono, Stan B. Kaye	745
19	Phase I Pharmacokinetic and Pharmacodynamic Study of Carboplatin and Topotecan Administered Intravenously Every 28 Days to Patients with Malignant Solid Tumors 2009 ·Clinical Cancer Research ·David S. Boss, (unknown), (unknown), Dick Pluim, Hilde Rosing, W.W. ten Bokkel Huinink, Jos H. Beijnen, Jan H.M. Schellens	1
20	Differential effects of the breast cancer resistance protein on the cellular accumulation and cytotoxicity of 9-aminocamptothecin and 9-nitrocamptothecin. 2003 ·PubMed ·(unknown), Murugesan Gounder, Ahamed Saleem, Jan H.M. Schellens, Douglas D. Ross, Susan E. Bates, Patrick J. Sinko, Eric H. Rubin	54

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact